Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.

Weisel K, Doyen C, Dimopoulos M, Yee A, Lahuerta JJ, Martin A, Travers K, Druyts E, Toor K, Abildgaard N, Lu J, Van Droogenbroeck J, Geraldes C, Petrini M, Voillat L, Voog E, Facon T.

Leuk Lymphoma. 2017 Jan;58(1):153-161.

PMID:
27124703
2.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators..

N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016.

3.

Improving Survival in Patients Treated for a Lung Cancer Using Self-Evaluated Symptoms Reported Through a Web Application.

Denis F, Yossi S, Septans AL, Charron A, Voog E, Dupuis O, Ganem G, Pointreau Y, Letellier C.

Am J Clin Oncol. 2015 Mar 24. [Epub ahead of print]

PMID:
25811297
4.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators..

N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321.

5.

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P.

Eur J Cancer. 2015 Jan;51(1):45-54. doi: 10.1016/j.ejca.2014.10.009.

PMID:
25459391
6.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team..

N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

7.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators..

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095.

8.

Detection of lung cancer relapse using self-reported symptoms transmitted via an internet web-application: pilot study of the sentinel follow-up.

Denis F, Viger L, Charron A, Voog E, Dupuis O, Pointreau Y, Letellier C.

Support Care Cancer. 2014 Jun;22(6):1467-73. doi: 10.1007/s00520-013-2111-1.

PMID:
24414998
9.

Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).

Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, Bellmunt J, Peters F, Le-Guennec S, Cerbone L, Risse ML, Machiels JP.

Oncology. 2013;85(4):208-15. doi: 10.1159/000354085.

PMID:
24080920
10.

Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up.

Denis F, Viger L, Charron A, Voog E, Letellier C.

Support Care Cancer. 2014 Jan;22(1):79-85. doi: 10.1007/s00520-013-1954-9.

PMID:
23995815
11.

The translocation t(4;14) can be present only in minor subclones in multiple myeloma.

Hébraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lodé L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H.

Clin Cancer Res. 2013 Sep 1;19(17):4634-7. doi: 10.1158/1078-0432.CCR-12-3866.

12.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators..

N Engl J Med. 2012 Sep 27;367(13):1187-97.

13.

Minor clone provides a reservoir for relapse in multiple myeloma.

Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, Marit G, Hulin C, Casassus P, Tiab M, Voog E, Randriamalala E, Anderson KC, Moreau P, Munshi NC, Minvielle S.

Leukemia. 2013 Feb;27(2):473-81. doi: 10.1038/leu.2012.226.

14.

Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.

Gimenez E, Chauvet M, Rabin L, Puteaud I, Duley S, Hamaidia S, Bruder J, Rolland-Neyret V, Le Gouill S, Tournilhac O, Voog E, Maisonneuve H, Jacob MC, Leroux D, Béné MC, Formisano-Tréziny C, Gabert J, Gressin R, Callanan MB.

Br J Haematol. 2012 Jul;158(2):186-97. doi: 10.1111/j.1365-2141.2012.09161.x.

PMID:
22626453
15.

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P.

J Clin Oncol. 2012 Jun 1;30(16):1949-52. doi: 10.1200/JCO.2011.36.5726.

PMID:
22547600
16.

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.

Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K.

Eur J Cancer. 2012 Mar;48(5):721-7. doi: 10.1016/j.ejca.2012.01.011. Review.

PMID:
22317952
17.

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR.

Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014.

PMID:
22129890
18.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM)..

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x.

PMID:
22023551
19.

2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group.

Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quéré I, Levesque H, Debourdeau P; SOR..

Crit Rev Oncol Hematol. 2010 Jan;73(1):31-46. doi: 10.1016/j.critrevonc.2008.12.004. Review.

PMID:
19801193
20.

2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.

Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; Working group of the SOR.; French National Feberation of Cancer Centers..

Ann Oncol. 2009 Sep;20(9):1459-71. doi: 10.1093/annonc/mdp052. Review.

PMID:
19525362

Supplemental Content

Loading ...
Support Center